Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden

Authors: Arturas Dobilas, Filip Jansåker, Xinjun Li, Kristina Sundquist, Christer Borgfeldt

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Associations between different cancer types are known. The affirmation of the risk for non-ovarian cancer after ovarian borderline tumors (BOT) is, however, sparse.

Aim

To analyze the risk of subsequent or simultaneous cancers in women with BOTs compared with the general female Swedish population.

Methods

An open cohort study (1995–2018) was conducted where a diagnosis of BOTs as well as subsequent or simultaneous cancer diagnoses were obtained from the Swedish Cancer Register and matched to the Total Population Register. Each woman with BOT was followed until non-ovarian cancer, death or emigration and could only be included once for the outcome. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) for specific non-ovarian cancers were analyzed.

Results

The 4998 women with serous and mucinous BOTs were diagnosed during 1995–2018 with a mean age of 55.7 years (SD 16.0) at diagnosis. Compared with the general female population, women with BOTs had increased risks for non-ovarian cancer in colon (SIR = 2.5; 95% CI 2.0–3.1), rectum (SIR = 1.7; 95% CI 1.1–2.5), small intestine (SIR = 5.0; 95% CI 2.3–9.5), cervix (SIR = 2.5; 95% CI 1.4–4.2), endometrium (SIR = 2.4; 95% CI 1.9–3.1), pancreas (SIR = 2.3; 95% CI 1.4–3.5), upper aerodigestive tract (SIR = 2.2; 95% CI 1.2–3.8), lung (SIR = 1.8; 95% CI 1.4–2.3), kidney (SIR = 2.3; 95% CI 1.4–3.7) and bladder (SIR = 1.8; 95% CI 1.1–2.8). Among women with serous BOTs, the risk of thyroid gland cancer (SIR = 3.1; 95% CI 1.2–6.4) was also increased. Lung and pancreas cancer showed increased risks more than 1 year after a diagnosis of BOT.

Conclusions

This Swedish population-based study demonstrated an increased risk of multiple malignancies including lung and pancreatic cancers beyond the first year of diagnosis in patients with borderline ovarian tumors (BOTs), suggesting a potential shared etiology.
Appendix
Available only for authorised users
Literature
1.
Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–47.PubMedPubMedCentral
2.
Baandrup L, Faber MT, Aalborg GL, Kjaer SK. Borderline ovarian tumors in Denmark 1997–2018: time trends in incidence by histology, age and educational level. Acta Obstet Gynecol Scand. 2021;100(3):436–43.PubMed
3.
Kurman RJ. WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer; 2014.
4.
Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017;41:15–30.PubMed
5.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705.PubMed
6.
Kalapotharakos G, Högberg T, Bergfeldt K, Borgfeldt C. Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960–2007. Acta Obstet Gynecol Scand. 2016;95(4):473–9.PubMed
7.
van Niekerk CC, Vooijs GP, Bulten J, van Dijck JA, Verbeek AL. Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor. Mod Pathol. 2007;20(3):384–8.PubMed
8.
Hung YP, Liu CJ, Hu YW, Chen MH, Li CP, Yeh CM, et al. Secondary primary malignancy risk in patients with ovarian cancer in Taiwan: a nationwide population-based study. Medicine (Baltimore). 2015;94(38):e1626.PubMed
9.
Yang Z, Liu X, Yang X, Liao QP. Second primary malignancies after ovarian cancer: a SEER-based analysis (1975–2016). Taiwan J Obstet Gynecol. 2022;61(1):80–5.PubMed
10.
Hunter MI, Ziogas A, Flores F, Brewster WR. Epithelial ovarian cancer and low malignant potential (LMP) tumors associated with a lower incidence of second primary breast cancer. Am J Clin Oncol. 2007;30(1):1–7.PubMed
11.
Bouchardy C, Fernandez S, Merglen A, Usel M, Fioretta G, Rapiti E, et al. Increased risk of second cancer among patients with ovarian borderline tumors. Gynecol Oncol. 2008;109(2):210–4.PubMed
12.
Levi F, Randimbison L, Blanc-Moya R, La Vecchia C. Second neoplasms after invasive and borderline ovarian cancer. Eur J Cancer Prev. 2009;18(3):216–9.PubMed
13.
Sanci M, Gultekin E, Cingillioglu B, Gultekin OE, Ozvural S, Emirdar V, et al. Second primary cancers following borderline ovarian tumors. Arch Gynecol Obstet. 2011;283(6):1391–6.PubMed
14.
Hannibal CG, Baandrup L, Hertzum-Larsen R, Vang R, Kurman RJ, Frederiksen K, et al. Risk of nonovarian cancer in a nationwide-based study of nearly 5000 women with borderline ovarian tumors in Denmark. Int J Cancer. 2023;152(7):1370–7.PubMed
15.
Hannibal CG, Frederiksen K, Vang R, Kurman RJ, Kjaer SK. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide study. Int J Cancer. 2020;147(4):990–5.PubMed
16.
Hemminki K, Li X. Level of education and the risk of cancer in Sweden. Cancer Epidemiol Biomarkers Prev. 2003;12(8):796–802.PubMed
17.
18.
Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.PubMed
19.
Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaëlsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125–36.PubMed
20.
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.PubMedPubMedCentral
21.
22.
23.
Rothman KJ, Greenland S, Lash TL. Types of epidemiologic studies. Mod Epidemiol. 1998;3:95–7.
24.
Estève J, Benhamou E, Raymond L. Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ. 1994;128:1–302.
25.
Gram IT, Braaten T, Adami HO, Lund E, Weiderpass E. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer. Int J Cancer. 2008;122(3):647–52.PubMed
26.
Schneider IJC, Schmidt TP, Correa VP, Santos A, Rocha BVD, Garcia LP, et al. Tobacco-related neoplasms: survival analysis and risk of death of population data from Florianópolis, SC. Rev Saude Publica. 2022;56:16.PubMedPubMedCentral
27.
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–61.PubMed
28.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.PubMedPubMedCentral
29.
Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control. 2013;24(5):989–1004.PubMed
30.
Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15–25.PubMed
31.
Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat Commun. 2017;8:14755.PubMedPubMedCentral
32.
Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306–16.PubMed
33.
Ji W, Xie H, Wei B, Shen H, Liu A, Gao Y, et al. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma. Int J Clin Exp Pathol. 2019;12(9):3492–9.PubMedPubMedCentral
34.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMed
35.
Park JM, Kim MK. Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry. J Menopausal Med. 2014;20(1):14–20.PubMedPubMedCentral
36.
Matrone A, Ferrari F, Santini F, Elisei R. Obesity as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2020;27(5):358–63.PubMed
37.
Wang P, Lv L, Qi F, Qiu F. Increased risk of papillary thyroid cancer related to hormonal factors in women. Tumour Biol. 2015;36(7):5127–32.PubMed
38.
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001;83(3):575–85.PubMed
39.
Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(Suppl 10):x16-21.PubMed
40.
Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470(2):125–42.PubMed
41.
Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449–55.PubMed
42.
Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. Int J Gynecol Cancer. 2020;30(11):1803–10.PubMed
43.
Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, et al. BRCA testing and outcomes in women with breast cancer. Breast Cancer Res Treat. 2021;186(3):839–50.PubMed
44.
Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(40):e4975.PubMed
45.
46.
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79.PubMedPubMedCentral
47.
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-49.e15.PubMed
Metadata
Title
Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden
Authors
Arturas Dobilas
Filip Jansåker
Xinjun Li
Kristina Sundquist
Christer Borgfeldt
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11453-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Registry-derived stage (RD-Stage) for capturing cancer stage at diagnosis for endometrial cancer

Research

The effect of specimen processing time on HER2 expression in gastric cancer and esophagogastric junction cancer: a single-center retrospective observational study

Research article

Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer: metabolic biomarkers and biological implications

Research

PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers

Research

Malnutrition and visceral obesity predicted adverse short-term and long-term outcomes in patients undergoing proctectomy for rectal cancer

Correction

Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits